Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.

Leukemia research - 1 Jun 2009

Sar Aylin, Perizzolo Marco, Stewart Doug, Mansoor Adnan, Difrancesco Lisa M, Demetrick Douglas J

Abstract excerpt

BACKGROUND: Rituximab, a chimeric antibody targeted to the human CD20 molecule, is a major component of the R-CHOP protocol used to treat patients with diffuse large B cell lymphoma (DLBCL). It is also a very expensive drug. Though the response rate of R-CHOP is higher than that of CHOP alone, patients may still experience a poor response. One possible mechanism that may mediate the poor response to R-CHOP is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Doxorubicin

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prednisone

Share to Rituximab

Share to Vincristine

Source

Identifiers

PMID: 19054557
DOI: 10.1016/j.leukres.2008.10.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.PMID 19054557Read ↗

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.Semantic proximity Read ↗

Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's LymphomaSemantic proximity Read ↗

The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma.Semantic proximity Read ↗

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.Semantic proximity Read ↗

Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.Semantic proximity Read ↗

Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas.Semantic proximity Read ↗

Selection of B-cell chronic lymphocytic leukemia cell variants by therapy with anti-CD20 monoclonal antibody rituximab.Semantic proximity Read ↗

VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.Semantic proximity Read ↗

Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.Semantic proximity Read ↗

The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast.Semantic proximity Read ↗

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.Semantic proximity Read ↗

BCL10 somatic mutations rarely occur in gastric lymphoma: detection of high frequency of polymorphisms in BCL10 coding region.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.